SUMMARY
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in Korea [1] . It is also the second and the fourth leading cause of cancer mortality in Korean women and men, respectively, although relatively easy prevention could be expected for CRC based on the slow development of tumors in the adenoma-carcinoma sequence [2] . Low compliance associated with the CRC screening modalities, including fecal occult blood test (FOBT)-based screening and lower endoscopic examinations, may partly contribute to the late detection and high mortality in advanced stages of the cancer, although the screening rate (55.6%) for CRC has increased steadily in Korea since 2004 [2, 3] . Many researchers have focused their attention on the development of a bloodbased screening tool using circulating cell-free tumor DNA in order to overcome the limitations relating to unappealing and inadaptable procedures [3] . Not only genetic mutations but also aberrant epigenetic changes of certain genes in tumorigenesis have been reported in multiple studies [4] [5] [6] [7] [8] . Methylated Septin 9 (mSEPT9) has been suggested as one of the most potent bloodbased tumor markers among various candidate genes in CRC [3, 7, 9] . Methylation of Septin 9 (SEPT9) is involved in cancer cell proliferation by silencing tumor suppressor genes, and this process has been extensively described for CRC [9] [10] [11] [12] . The current study aimed to investigate the status of mSEPT9 in Korean patients with CRC and compared the results with those of previous studies.
MATERIALS AND METHODS

Subjects and samples
A total of 127 plasma samples from 111 patients with untreated CRC, 5 patients with benign adenomas (1 hyperplastic and 4 tubulovillous adenomas), and 11 CRC patients treated with concurrent chemoradiotherapy (CCRT) before surgery were prospectively collected at Korea Cancer Center Hospital between June 2013 and August 2014. This study was conducted according to the guidelines of the Declaration of Helsinki. All subjects underwent pathological verification after lower endoscopic evaluation. Additionally, 21 follow-up samples from CRC patients positive for mSEPT9 at the time of diagnosis were collected after curative surgery and CCRT. The patients' clinical records, including disease status, tumor stage, and other laboratory data, were reviewed. This study was approved by the Korea Cancer Center Hospital Institutional Review Board (K-1305-001-003), and all patients provided written informed consent.
Laboratory methods Sample preparation
All samples were collected after the provision of informed consent. We obtained 20 mL of whole blood samples in 10 mL EDTA-K2 tubes. Blood samples were kept at 4°C before centrifugation. The samples were centrifuged at room temperature at 1,350 g for 12 minutes to separate plasma within 24 hours of collection, and then were centrifuged again under the same conditions. After centrifugation, the plasma was transferred into 1.5 mL tubes without disturbing the buffy coat layer. Prepared plasma samples were frozen at -80°C until the time of analysis. The minimum volume of plasma for analysis was 4.0 mL according to the manufacturer's instruction. We set a minimum of 4.3 mL to avoid volume error. Based on the magnetic particle method, DNA was extracted with an Abbott mSample Preparation System DNA kit (Abbott Laboratories, Abbott Park, IL, USA) according to the manufacturer's instructions. Bisulfite DNA modification was performed using the Abbott Bisulfite Modification Kit (Abbott Laboratories) according to the manufacturer's protocols. Again, DNA was isolated and purified with the Abbott mSample Preparation System DNA kit and prepared for real-time polymerase chain reaction (PCR).
Qualitative measurement of mSEPT9 DNA Real-time PCR was carried out on an Abbott m2000rt instrument (Abbott Laboratories). One positive control (SEPT9) and one negative control (beta-actin) per run were included. The results were analyzed qualitatively depending on their characteristic PCR curves, and positive results were reported when at least one of three replicates exceeded the cutoff level provided by the commercial kit (Abbott RealTime mS9 Colorectal Cancer Assay System, Abbott Laboratories).
Statistical analysis
The Chi square test or Fisher's exact test was used to compare the mSEPT9 frequency distribution of clinicopathologic features, including gender, tumor stages, pathologic diagnosis, and different locations. The nonparametric Mann-Whitney U test was used to compare the means of quantitative values of age, carcinoembryonic antigen (CEA) level, and cancer antigen 19-9 (CA 19-9) level according to mSEPT9 status. All of the p-values were two-sided, and p < 0.05 was considered to be statistically significant. Statistical analysis was performed with SPSS version 19.0 (IBM Corp., Armonk, NY, USA).
RESULTS
mSEPT9 in colorectal cancer patients mSEPT9 was detected in 44 of 111 (39.6%) patients with untreated CRC but was not detected in the patients with adenomas (Table 1 ). In addition, negative mSEPT9 results were shown in all patients (11 of 11, 100%) treated with concurrent chemoradiotherapy before surgery ( Table 2 ). All of these patients (11 of 11) were diagnosed with a rectal cancer and were treated with fluorouracil-based chemotherapy and radiotherapy about two months before curative resection.
Correlation of mSEPT9 status with clinicopathologic features
We analyzed the relationships between the detection of mSEPT9 in CRC patients and various clinicopathologic features ( Table 1) . The difference in the rates of detection of mSEPT9 among patients with adenomas and those with each stage of CRC was statistically significant (Dukes' staging, p = 0.002 and TNM staging, p = 0.008). The positive fractions for each TNM stage among untreated patients were 6 of 29 (20.7%) for stage 
Follow-up of mSEPT9 after treatment
Twenty-one of 44 CRC patients who had positive results before undergoing treatments participated in the follow-up study. The samples were collected for 201 days on average (range: 78 -321 days) after surgery and chemoradiotherapy. The positive mSEPT9 results in the untreated CRC patients reverted to negative in 19 of 21 CRC patients (90.5%) after the treatments (Table 2) .
Two patients remained positive for mSEPT9 in the follow-up study, and CEA and CA 19-9 levels were within the normal range from the time of diagnosis to followup in both patients. One of the patients was classified as having stage IIIB disease and the tumor was completely resected. The patient refused adjuvant chemotherapy during two cycles of the folinic acid-fluorouracil-oxaliplatin (FOLFOX) regimen. Follow-up of mSEPT9 204 days after surgery showed that it was still positive although imaging studies and laboratory data found no evidence of tumor recurrence. The other patient was stage IVA and underwent surgery before 321 days. At the time of the follow-up study, he was undergoing palliative treatment with a modified FOLFOX6 regimen. Abdominal computed tomography (CT) revealed aggravated multiple retroperitoneal lymph node metastases. At the time of this writing, the former patient diagnosed stage IIIB rectal cancer was still alive without relapse but the latter patients diagnosed stage IVA rectal cancer were dead with aggravation of lung metastases despite further chemotherapies with modified FOLFOX6.
DISCUSSION
Currently the application of methylation-based biomarkers in conjunction with circulating cell-free tumor DNA is opening a new era of non-invasive approaches to cancer detection [3] [4] [5] [6] [7] [8] [9] [10] [11] . The septin genes are involved in several cancers in deregulating cell processes at various levels, including tumor suppression and tumor promoting activity [12] . The hypermethylation of the SEPT9 gene leads to the silencing of tumor suppressor genes in tumorigenesis and has been consistently identified mainly in colorectal and head and neck cancers [3, [12] [13] [14] . In particular, SEPT9_v2, one of the splice variants in the promoter region, is known to be highly specific for CRC [7, 15] . A wide range of sensitivities between 37% and 90% have been reported in various studies of mSEPT9 for CRC [16] [17] [18] [19] [20] [21] [22] . In this study, the overall sensitivity of mSEPT9 for CRC was relatively low (39.6%) compared to the findings of previous studies ( Table 3 ). The previous study of mSEPT9 using the same kit as this study, based on a Korean CRC population, also revealed low sensitivity (36.6%, Table 3 ) although minor variations in sample collection and processing could exist between the studies [21] . Most prior studies regarding mSEPT9 as a marker for CRC have been performed employing the Epi proColon Kit (Epigenomics AG, Berlin, Germany) or preliminary research kits in the US and Germany and were based on populations comprising Caucasians in Western countries [16] [17] [18] [19] . Therefore, not only differences in methodologies or kits but also ethnic or sociocultural differences might be affecting the mSEPT9 results [11, 23] . In addition, there might be potential differences in sample collection, processing, and storage methods. Recent studies have reported improved sensitivity (68 -96%) with changes in several levels, including elimination of PCR inhibition, simplified and accelerated handling procedures, and added automated potential [18] [19] [20] 24] . Strategies for CRC screening aim for early detection during the colorectal adenoma-carcinoma sequence. However, the sensitivity of mSEPT9 in patients with premalignant lesions including tubulovillous adenoma and/or hyperplastic polyps and early stages of CRC was very low (5 -29% and 25 -62%, respectively) in previous reports [3, 4, 9, [16] [17] [18] [19] [20] [21] [22] . The equilibrium between the release of DNA by living cells and the clearance of DNA might still be maintained, or fundamental barriers to the detection of DNA markers might exist in premalignant lesions or early stages of CRC [16, 24] . In order to overcome the difficulty of detecting low-concentration methylated tumor DNA in a very high background, collecting a large volume of plasma as well as using more sensitive PCR detection methods have been suggested [25] . However, this screening method may have disadvantages in individuals who fear phlebotomy, particularly the collection of large volumes of over 10 mL of whole blood for one test. As the preference among several screening modalities for CRC can differ by race/ethnicity, more research regarding the preferences of the general population could be helpful for the introduction of a new screening method [26, 27] . In general, tumor-induced lymphangiogenesis facilitates metastasis to lymph nodes in proportion to tumor stage, although the mechanism of tumor invasion is not yet fully understood [28] . Interestingly, in the analysis of our data we found that higher detection of mSEPT9 was present in stage II than in stage III (54.1% vs. 35.7%, Tables 1 and 3 ). According to the TNM classification, stage II and stage III are divided by the existence of lymph node invasion. A progressive increase not only in the concentration of mSEPT9 DNA but also in the detection rate of mSEPT9 across stages has been noted in several studies [3, 29, 30] . However, different stages of tumorigenesis might not be mainly associated with methylation. A lack of correlation with stage was also observed in various studies (Table 3 ) [16] [17] [18] [19] [20] [21] . Grutzmann et al. reported that there was no significant quantitative difference between amounts of mSEPT9 DNA between different stages [3] . In addition, Denese et al. speculated that more activated mSEPT9 DNA in early tumorigenesis might be transferred from the epithelium to stromal cells, which move into the circulation [8] . Furthermore, the increased inflammatory and tumor-related factors in the advanced stages (stages III/IV and Dukes' C) might have an effect on the lower rates of mSEPT9 detection [9] . In the context of ambiguous characterization between stage II and stage III, clinicians also experience difficulty in decisions regarding treatment with adjuvant chemotherapy between stage II and stage III [30, 31] . Recent studies have suggested that molecular biomarkers may have a stage-specific distribution and prognostic value [32, 33] . Further studies supporting our results are expected with elucidation of the underlying mechanisms of tumor invasion to the vascular system in conjunction with tumor-related methylated cell-free DNA in plasma. Additionally, a potential benefit of mSEPT9 as a follow-up marker was observed in our study, in which the conversion to negativity of mSEPT9 in patients during follow-up was highly correlated with clinical status judging from imaging studies, tumor markers, and physical status. Larger studies with long follow-up periods would be expected to show the predictive effects of mSEPT9 in CRC. Unfortunately, uneven distribution of patients between stages, especially small numbers of patients with premalignant lesions and stage IV CRC patients, can lead to rather imprecise estimates of performance characteristics. Thus, we grouped the four TNM and Dukes' stages into two stages, early (I + II and A + B) and late (III + IV and C + D) stages, due to the unequal distribution of each stage, particularly the limited number of stage IV patients and the relatively large number of stage II and III patients. No significant differences were shown between the early and late stages (p = 0.627 and p = 0.949 for Dukes' staging and TNM staging, respectively).
Further validation with larger enrollments in each stage, comprising a variety of ethnicities and premalignant diseases, and employing evaluation of different kits should be performed for the introduction of the mSEPT9 assay as a routine CRC screening method. Furthermore, the subjects were not enrolled from the screening population. Most of them were identified by symptoms and then underwent colonoscopy.
CONCLUSION
The overall sensitivity of mSEPT9 as a diagnostic marker for CRC was lower, but similar patterns of sensitivities between stages were observed, in comparison to previous studies. Additionally, mSEPT9 appeared to have potential as a monitoring marker for risk assessment.
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